EGFR and lung adenocarcinoma: The main aim of this study was to understand how major driver mutations related to EGFR (L858R and/or Ex19del) affect downstream molecular networks and pathways, which would reflect disease nature and treatment outcomes in patients with lung adenocarcinoma (most abundant among NSCLC subtypes) who harbour these EGFR mutations.